|
Jan 22
|
Karuna, Cerevel might be just the start of psychiatry drug M&A
|
|
Jan 20
|
Opdivo (nivolumab) Plus Yervoy (ipilimumab) Reduced the Risk of Disease Progression or Death by 79% Versus Chemotherapy in Patients with Microsatellite Instability-High or Mismatch Repair Deficient Metastatic Colorectal Cancer in CheckMate -8HW Trial
|
|
Jan 20
|
Retirement Stock Portfolio: 12 Healthcare Stocks To Consider
|
|
Jan 18
|
Drugmakers Raise Prices of Ozempic, Mounjaro and Hundreds of Other Drugs
|
|
Jan 17
|
Bristol Myers Squibb Data at ASCO GU 2024 Showcase Transformative Research in the Treatment of Genitourinary Cancers
|
|
Jan 16
|
Bristol Myers Squibb (BMY) Sees a More Significant Dip Than Broader Market: Some Facts to Know
|
|
Jan 10
|
Prothena's (PRTA) Update on Pipeline Progress Disappoints
|
|
Jan 10
|
5 questions facing pharma in 2024
|
|
Jan 9
|
Here's Why Bristol Myers Squibb (BMY) Fell More Than Broader Market
|
|
Jan 6
|
3 Magnificent High-Yield Dividend Stocks to Buy in 2024
|
|
Jan 4
|
Agios (AGIO) Up 5% on Upbeat Data From Thalassemia Study
|
|
Jan 3
|
Bristol Myers Squibb (BMY) Dips More Than Broader Market: What You Should Know
|
|
Jan 3
|
Bristol Myers (BMY) NSCLC Drug Application Gets EMA Validation
|
|
Jan 3
|
Bristol-Myers Squibb Co's Dividend Analysis
|
|
Jan 3
|
Bristol Myers Squibb Stock Opens Lower After Downgrade
|
|
Jan 2
|
European Medicines Agency Validates Bristol Myers Squibb’s Application for Repotrectinib for the Treatment of Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer and NTRK-Positive Solid Tumors
|
|
Dec 24
|
15 Undervalued Defensive Stocks For 2024
|
|
Dec 22
|
S&P 500 Gains and Losses Today: Nike Warns of Soft Sales and Plans Spending Cuts
|
|
Dec 22
|
Bristol's $14 Billion Takeover Of Karuna Pulled A Bevy Of Stocks Higher
|
|
Dec 22
|
Rocket Lab, Coinbase, Bristol Myers-Karuna deal: Trending tickers
|